EP Patent

EP3986410A4 — Patient selection for enhancement of anti-tumor immunity in cancer patients

Assigned to Pharmacosmos Holding AS · Expires 2023-06-28 · 3y expired

What this patent protects

Patent listed against trilaciclib-dihydrochloride.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP3986410A4
Jurisdiction: EP
Classification: —
Expires: 2023-06-28
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacosmos Holding AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.